CytoDyn Initiates Phase 2a Study of Leronlimab in Alzheimer’s Disease
Event summary
- First patient dosed in Phase 2a study evaluating leronlimab for Alzheimer’s disease.
- Study, named SALIENT-AD, is an open-label, proof-of-concept trial with 10–20 patients.
- Primary endpoint assesses changes in brain inflammation using advanced PET imaging.
- Collaboration led by Tracy Butler, MD, of Weill Cornell Medicine.
The big picture
CytoDyn’s Phase 2a study explores leronlimab’s potential in Alzheimer’s disease, targeting neuroinflammation—a growing focus in neurodegenerative research. While the company remains centered on oncology, this collaboration with Weill Cornell Medicine signals an expansion into high-unmet-need indications. Success in this trial could position leronlimab as a multi-indication therapy, broadening its market potential.
What we're watching
- Clinical Efficacy
- Whether leronlimab can demonstrate meaningful impact on neuroinflammation in Alzheimer’s patients.
- Regulatory Pathway
- The pace at which CytoDyn advances leronlimab beyond oncology into neurodegenerative diseases.
- Strategic Focus
- How CytoDyn balances Alzheimer’s research with its core oncology pipeline.
Related topics